XNAS · Healthcare · Biotechnology
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.44 | -0.42 | +4.55% | $0 | ✅ Beat | -0.55% | -7.36% | — |
| 2026-02-26 | Q4 2025 | -0.42 | -0.38 | +9.52% | $0 | mixed | +0.44% | +2.43% | -16.78% |
| 2025-11-06 |
| Q3 2025 |
| -0.50 |
| -0.45 |
| +10.00% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.55 | -0.62 | -12.73% | $0 | ❌ Miss | +0.00% | -1.94% | +6.15% |
| 2025-02-27 | Q4 2024 | -0.72 | -0.62 | +13.89% | $0 | ✅ Beat | +0.53% | -4.36% | -29.04% |
| 2024-11-07 | Q3 2024 | -0.76 | -0.71 | +6.58% | $0 | ✅ Beat | +1.16% | -14.09% | -19.77% |
| 2024-02-26 | Q4 2023 | -0.79 | -0.64 | +18.99% | $0 | ✅ Beat | — | — | — |
| 2023-11-06 | Q3 2023 | -0.81 | -0.75 | +7.41% | $0 | ✅ Beat | +2.71% | -2.11% | +29.60% |
Showing last 8 quarters.